Accueil / Communiqués / Triumvira Announces Addition of Veteran VP of Regulatory Affairs, Presentations at CellCAN and TRI-CON Conferences, and Attendance at Bio-Europe Partnering

Triumvira Announces Addition of Veteran VP of Regulatory Affairs, Presentations at CellCAN and TRI-CON Conferences, and Attendance at Bio-Europe Partnering

Wednesday, March 13th 2019 at 12:00pm UTC

AUSTIN, Texas & HAMILTON, Ontario–(BUSINESS WIRE)– Triumvira
Immunologics
(Triumvira), a privately held biopharmaceutical company
developing a novel platform for engineering T-cells to attack cancers,
today announced the appointment of Cynthia Molina as Vice President of
Regulatory Affairs. In this position, Cynthia will be responsible for
global regulatory strategic development, oversight of regulatory
submissions, and interactions with US and international governmental
health authorities.

Before joining Triumvira, Ms. Molina was most recently VP of Global
Regulatory Affairs at Cell Medica, Inc in Houston, TX, for 6 years and
accumulated 30 years of experience in multiple facets of product
development for pharmaceutical, biotechnology, biologic, and in vitro
diagnostic products, with a primary focus on regulatory affairs. In
addition to regulatory affairs, her experience includes clinical and
preclinical strategic planning, quality assurance, process development
and manufacturing for oncology and infectious disease products. Ms.
Molina has experience leading preparation of a variety of global
regulatory submissions, including INDs, NDAs, BLAs, MAAs, global CTAs,
510Ks, PMAs, orphan and Fast Track submissions, and clinical study
reports. She has held management positions at both large and small
corporations, including Abbott Laboratories.

Paul Lammers, MD, MSc., President and CEO of Triumvira commented, “We
are very pleased to welcome Cynthia to our management team. Her
background and experience in regulatory affairs will enhance our
interactions with regulatory agencies supporting our plan to bring
multiple TAC product candidates into clinical development alone, as well
as in collaboration with our business partners.”

Additionally, several Triumvira executives are presenting at upcoming
conferences. Triumvira Chief Technology Officer Donna Rill and Senior
Vice President of R&D Dr. Andreas Bader will present at CellCAN’s Second
Annual, Pan-Canadian Strategic Forum on Regenerative Medicine and Cell
Therapy, to be held March 13-15, 2019, in Toronto, ON. Director of R&D
and Head of Platform Development Dr. Christopher Helsen will present at
the 26th International Molecular Med Tri-Conference on March
14, 2019, in San Francisco, CA. Topics of their presentations will be:

Characterizing products for GMP manufacturing: What, how and when? (Ms.
D. Rill)

Optimizing cell and gene therapy manufacturing, Planning for Success
– the path to commercialization
(Ms. D. Rill)

TAC technology, its unique and novel MoA, preclinical data and
considerations for biomarker analysis in our Phase I/II trial
(Dr.
A. Bader)

Development of a CD19-TAC therapy for a first in human phase I study (Dr.
C. Helsen)

Triumvira also announces Joshua Carle, Vice President of Business
Development, will attend the Bio-Europe Spring Partnering conference in
Vienna, Austria from March 25–27, 2019. Mr. Carle and Triumvira are
seeking to find out-licensing partners to accelerate our TAC pipeline
development, collaborators with novel cancer cell surface antigens
looking to expand into engineered T-cells, and to identify
immuno-oncology assets that are complementary to our TAC T-cell platform.

About Triumvira Immunologics

Triumvira Immunologics, Inc. (Triumvira) is an immunotherapy company
co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and
Bloom Burton & Co., with the vision of developing novel T cell therapies
that are safer and more efficacious than current gene therapy cancer
treatments, including chimeric antigen receptor (CAR) and engineered T
cell receptor (TCR) therapies. Our proprietary T cell Antigen Coupler
(TAC) technology recruits the entire natural T cell receptor and is
independent of the Major Histocompatibility Complex (MHC), allowing for
the development of better therapies for a broader range of patients with
solid or liquid malignancies and with diseases other than cancer. With
operations spanning North America, our corporate offices are in Austin,
Texas, and our research facilities in Hamilton, Ontario. For more
information, visit www.triumvira.com or
send email inquiries to partners@triumvira.com.

Contacts

Triumvira Immunologics Inc.
LaVoieHealthScience
Katie
Gallagher
Phone: +1-617-374-8800, Ext. 109
kgallagher@lavoiehealthscience.com
www.triumvira.com
partners@triumvira.com

Source: Triumvira Immunologics


Voir aussi

Maverick Therapeutics to Unveil Pre-Clinical Data on Novel COBRATM Platform at American Association for Cancer Research 2019 Annual Meeting

Saturday, March 30th 2019 at 12:00pm UTC – Pre-clinical Data Characterize the Conditional and Potent …